<DOC>
	<DOCNO>NCT00464217</DOCNO>
	<brief_summary>To reproduce improve index complete response protocol LMA-91 similar protocol , decrease dose Idarubicin try reduce death induction</brief_summary>
	<brief_title>Treatment Acute Myeloblastic Leukaemia Patients Over 65 Years</brief_title>
	<detailed_description>INDUCTION TREATMENT : Ara-C 100 mg/m 2 /day continuous perfusion , day 1 - 7 . Idarubicin 8 mg/m 2 /day , day 1 - 3 bolus . GM-CSF ( Leucomax ) 5 mcg/kg subcutaneous endovenous day + 4 finish chemotherapy recovery neutropenia ( &gt; 1.000/mm 3 ) CONSOLIDATION TREATMENT The patient reach complete response first cycle , receive second cycle consolidation . The patient reach complete response first cycle receive second cycle . If two cycle , obtain response , patient leave protocol . INTENSIFICATION TREATMENT All patient complete response one cycle induction one cycle consolidation , two cycle induction , receive treatment intensification : ARA-C 500 mg/m 2 /12 h one hour infusion , day 1-4 . Daunomycin 45 mg/m 2 /day bolu , day 5-7 . GM-CSF ( Leucomax ) : 5 mcg/kg day + 4 finish chemotherapy recovery neutropenia ( &gt; 1.000/mm 3 )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Cytologic diagnosis acute myeloblastic leukaemia ( excluded M3 ) Over 65 year Previous diagnosis malignancy hematopoietic disorder myelodysplastic syndrome Previous treatment antileucemic chemotherapy Psychiatric disorder Diagnosis subtype FAB M3 Creatinine &gt; 2.5 mg/dL Bilirubin , Alkaline Phosphatase transaminases three time upper limit</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Acute Myeloblastic Leukaemia</keyword>
</DOC>